# Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)

> **NCT01974687** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 178 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Uprifosbuvir
- **DRUG:** Placebo
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT01974687
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-31
- **Primary completion:** 2015-09-02
- **Final completion:** 2015-09-11
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2018-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01974687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01974687, "Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01974687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*